Clinical trials: Refractory Solid Tumor
Malignant Solid Tumors, Other Neoplasms Solid Tumors
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial.
- Conditions
- Malignant Solid Tumors, Other Neoplasms Solid Tumors, Pediatric Solid Tumor, Refractory Solid Tumors
- Trial name
- NCT03739827
- Where
- 3 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400225
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Refractory to Standard Therapy
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
This is a single-center, double-blind, single-dose escalation study in healthy volunteers.
- Trial name
- NCT04026321
- Testing
- SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Refractory Solid Tumors, Lymphomas
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled, three-treatment, three-way crossover study in healthy subjects. There are two phases in this study: Pre-Randomization and Randomization.
- Trial name
- NCT01525394
- Testing
- Lenvatinib, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they would want if they were unable…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Refractory Hematologic Malignancy
- Trial name
- NCT04515810
- Testing
- Internet-Based Intervention, Best Practice, Telephone-Based Intervention
- Where
- 4 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT04270461
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jiujiang University Affiliated Hospital